Background/aims: Patients taking hydroxychloroquine (HCQ) are at risk of developing classic bull's eye maculopathy. Currently, the standard Amsler grid (AG) is one of the most useful methods to identify such lesions. However, AG is a suprathreshold target and may not detect relative central scotomas. The aim of this study was to determine if the threshold Amsler grid (TAG) test, which varies light transmission through two cross polarising filters, allows increased detection of scotomas caused by HCQ toxicity. Methods: 56 rheumatological patients taking HCQ and 12 similar patients not taking HCQ were tested by AG, red Amsler grid (RAG), and TAG. Results: No scotomas were observed in patients never treated with HCQ. Among patients who had been treated with HCQ, AG revealed scotomas in two of 56 (3.64%) patients; in contrast, six (10.7%) and 37 (66.1%) scotomas were identified by RAG and TAG testing respectively. Additionally, the average area of each scotoma detected by all three methods expanded from 34.5 square degrees of central field loss on AG testing to 71 square degrees on RAG and 117 on TAG. Conclusion: By decreasing the perceived luminance of the suprathreshold AG, TAG testing provides a novel alternative to detect shallow scotomas and areas of depressed retinal activity secondary to HCQ toxicity.
In the TRIPOD study, troglitazone` treatment of Hispanic women with prior gestational diabetes (GDM) reduced the incidence of type 2 diabetes by 55%, from 12.1% to 5.4% per year in a manner that was closely related to reduction of endogenous insulin requirements effected by amelioration of insulin resistance. Women who completed the TRIPOD study and post-trial drug washout were asked to participate in the Pioglitazone in Prevention of Diabetes (PIPOD) study if their HbA1C was ≤7%. Women were placed on pioglitazone, 45 mg/d, for a scheduled three years plus six months off-drug washout. Fasting glucose levels were measured at three month intervals during drug treatment and 6-month post-trial drug washout. Oral glucose tolerance tests were performed annually and at the end of the post-trial washout. Intravenous glucose tolerance tests (IVGTTs) performed at baseline and one year later were used to assess the initial impact of pioglitazone on insulin resistance and insulin responses. Data for this report were analyzed to assess the incidence of type 2 diabetes and its relationship to initial β-cell unloading in the 86 women who entered PIPOD without diabetes. The annual diabetes incidence rate in those women during a median follow-up of 3.4 years was 4.6%. Seventy of the women had an IVGTT at baseline and one year later. Mean initial β-cell unloading, calculated as the fractional change in total IVGTT insulin area between baseline and year 1, was 26%. Based on the relationship between initial β-cell unloading and diabetes incidence in TRIPOD, this initial loading in PIPOD predicts a 5.3% annual diabetes risk. The observed rate in the 70 women with baseline and 1-year IVGTTs was 5.4%/yr. Annual diabetes rates in tertiles of the cohort defined by initial β-cell unloading were 6.5%/yr, 3.8%/yr and 1.1%/yr for (smallest to largest unloading). Thus, treatment with pioglitazone in Hispanic women with prior GDM was associated with a relatively low annual diabetes rate that tracked closely with the degree of initial β-cell unloading induced by the drug.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.